SNDX stock news

This page provides real-time market news, earnings updates, and company announcements related to Syndax Pharmaceuticals, Inc. (SNDX).

All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.

Last updated as of 2026-02-27 14:46 EST

BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact

Finviz2026-02-14 06:30:12

Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales

Finviz2026-02-20 09:12:44

Syndax Announces Participation in March Investor Conferences

Finviz2026-02-23 12:03:47

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Finviz2026-02-26 21:03:45

Syndax: Overview of Fourth Quarter Financial Results

101 finance2026-02-26 21:54:42

Syndax Pharmaceuticals, Inc. announces that patient enrollment has been completed for its Phase II clinical trial of Axatilimab for idiopathic pulmonary fibrosis (IPF).

老虎证券2026-02-26 22:14:06

SNDX stock chart

SNDX stock details

SNDX stock price change

On the last trading day, SNDX stock closed at 20.48 USD, with a price change of -1.30% for the day.

Trade stock perps

About Bitget

The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).

SNDX stock news